# THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

> **NCT06559891** · NA · RECRUITING · sponsor: **SoniVie Inc.** · enrollment: 261 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DEVICE:** TIVUS™ Renal Denervation System
- **OTHER:** Sham

## Key facts

- **NCT ID:** NCT06559891
- **Lead sponsor:** SoniVie Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-03
- **Primary completion:** 2027-03-31
- **Final completion:** 2028-08-15
- **Target enrollment:** 261 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06559891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06559891, "THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06559891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*